Addition of sildenafil in adult patients with CHD-related PAH and Eisenmenger syndrome after oral bosentan therapy failure is safe and well tolerated at 6-month follow-up , resulting in a significant improvement in clinical status , effort SpO ( 2 ) , exercise tolerance and haemodynamics .
